The combination of sacubitril and valsartan reduces the cardiotoxicity related to anthracycline chemotherapy drugs, according to the first randomized study of this approach.
, cuts the risk for cardiomyopathy after chemotherapy in patients who received anthracycline drugs by 77% in the first randomized controlled study of this approach.
“There was a significant reduction in cardiotoxicity with the medication,” said investigator Marcely Bonatto, MD, from the University of São Paulo, São Paulo, Brazil. “It showed a good safety profile, with no serious adverse events or increase in treatment discontinuation,” she reported at the The study participants were chosen because they had evidence of cellular damage after their chemotherapy dose, defined as an increase in high-sensitivity troponin I above the 99th percentile.The combination of sacubitril-valsartan, approved by the US Food and Drug Administration in 2015, contains an angiotensin receptor and a neprilysin inhibitor . The two drugs act on “two neural-hormonal mechanisms that are put in place by our body to deal with heart failure,” said Tochi M.
Case reports, case series, and two pilot studies assessed the cardioprotective effects of sacubitril-valsartan during chemotherapy, but the pilot studies were small and did not compare the drugs with placebo or other medications, Okwuosa said. SARAH, as the first randomized controlled study of the drug combination, is an important step toward its use during chemotherapy.
Combination Chemotherapy Combination Drug Therapy Heart Failure Chemotherapy Heart Hypertension Toxicology Toxicity Poisoning Toxins Cardiotoxicity Anthracyclines Lung Cancer Lung Carcinoma Cancer Of The Lung Leukemia Leukaemia Blood Cancer Cancer Malignant Neoplasia Carcinoma Malignant Neoplasm Receptors
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Immunotherapy blocks scarring, improves heart function in mice with heart failureResearchers have reduced scar formation and improved heart function in mouse models of heart failure using a monoclonal antibody treatment, similar to that approved by the FDA to treat other conditions.
Read more »
VAD heart pump helps keep Delaware heart failure patient on the goWorsening heart failure threatened the travel and family time Herman Davis and his wife cherished. But for nearly 3 years, a heart pump called a VAD has given him a quality of life back.
Read more »
Limited Kidney Benefits With Finerenone in Heart FailureAn analysis of the FINEARTS-HF trial, which showed finerenone's benefits in heart failure outcomes, shows no significant effects on eGFR outcomes.
Read more »
Protein in soy may reduce the risk of heart failure by affecting gut bacteriaResearchers have found a potential method to slow heart failure progression. They fed mice a diet high in soybean protein, which influenced gut bacteria and supported heart health. Analysis showed that this diet increased the production of the short-chain fatty acids in the gut that help to protect the heart.
Read more »
Twins with heart failure call for end to healthcare 'lottery'Nicole and Farrah live just 32 miles away from each other, but are in different health trusts.
Read more »
Tirzepatide Reduces Heart Failure Events in HFpEF With ObesitySUMMT has shown for the first time that a drug can reduce major heart failure clinical outcomes in patients with heart failure and a preserved ejection fraction and obesity.
Read more »